DOCSLIB.ORG

GM Vaccines: from Bench to Bedside Bedside to Bench from Vaccines: GM 2014-08 CGM GM Vaccines: from Bench to Bedside ONDERZOEKSRAPPORT 08 - 2014 CGM

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
GM Vaccines: from Bench to Bedside Bedside to Bench from Vaccines: GM 2014-08 CGM GM Vaccines: from Bench to Bedside ONDERZOEKSRAPPORT 08 - 2014 CGM POSTBUS 578 3720 AN BILTHOVEN TEL.: 030 274 2777 FAX: 030 274 4476 [email protected] WWW.COGEM.NET CGM 2014-08 GM Vaccines: GM Vaccines: From bench to bedside From bench to bedside ONDERZOEKSRAPPORT ONDERZOEKSRAPPORT CGM 2014 - 08 2014 J.H.C.M. Kreijtz B. Ramezanpour K.D.S. Fernald L.H.M. van de Burgwal GM VACCINES: FROM BENCH TO BEDSIDE An investigation performed for The Netherlands Commission on Genetic Modification (COGEM) GM Vaccines: From Bench to Bedside 2014 © 2014 – COGEM and Viroscience Lab – All Rights Reserved Page | 2 GM Vaccines: From Bench to Bedside 2014 TABLE OF CONTENTS DISCLAIMER COGEM .............................................................................................................................................. 6 DISCLAIMER AUTHORS .......................................................................................................................................... 6 COPYRIGHT ............................................................................................................................................................ 6 AUTHORS ............................................................................................................................................................... 6 PREFACE ................................................................................................................................................................ 7 DELINEATION OF GENETICALLY MODIFIED VACCINE DEFINITIONS ......................................................................... 8 DEFINITIONS AND ABBREVIATIONS ....................................................................................................................... 9 VACCINE TYPES .................................................................................................................................................... 10 LIMITATIONS OF THIS STUDY ............................................................................................................................... 11 1. INTRODUCTION ........................................................................................................................................... 14 1.1 BACKGROUND ................................................................................................................................................ 14 1.2 PROJECT OUTLINE ........................................................................................................................................... 15 1.3 REPORT OUTLINE ............................................................................................................................................ 17 2. MARKET ...................................................................................................................................................... 20 2.1 METHODOLOGY .............................................................................................................................................. 20 2.2 REGISTERED GM VACCINES ............................................................................................................................... 22 2.3 VACCINE TARGET PATHOGENS ............................................................................................................................ 23 2.4 APPLICATION FIELDS ........................................................................................................................................ 24 2.5 VACCINE DEVELOPMENT/PRODUCTION TECHNOLOGIES ........................................................................................... 26 2.6 VACCINES FOR COMPANION ANIMALS .................................................................................................................. 29 2.7 EXOTIC ANIMAL VACCINES (WILDLIFE & ZOO) ....................................................................................................... 30 2.8 HIGHLIGHTS ................................................................................................................................................... 31 3. CLINICAL DEVELOPMENT ............................................................................................................................. 34 3.1 METHODOLOGY .............................................................................................................................................. 34 3.2 INDICATIONS .................................................................................................................................................. 36 3.3 VACCINE TECHNOLOGIES ................................................................................................................................... 39 3.4 VACCINE DEVELOPERS ...................................................................................................................................... 45 3.5 FUTURE EXPECTATIONS ..................................................................................................................................... 46 3.6 HIGHLIGHTS ................................................................................................................................................... 47 4. PRECLINICAL DEVELOPMENT ....................................................................................................................... 50 4.1 METHODOLOGY .............................................................................................................................................. 50 4.2 RESULTS ........................................................................................................................................................ 50 4.3 HIGHLIGHTS ................................................................................................................................................... 54 5. LATEST TRENDS ........................................................................................................................................... 56 5.1 NVGCT SPRING SYMPOSIUM 2014 - 14TH OF MARCH 2014 ................................................................................ 56 © 2014 – COGEM and Viroscience Lab – All Rights Reserved Page | 3 GM Vaccines: From Bench to Bedside 2014 TH 5.2 WORLD VACCINE CONGRESS 2014 - 24-26 OF MARCH 2014 .............................................................................. 56 TH 5.3 VACCINE TECHNOLOGY V - 8-13 OF JUNE 2014 ................................................................................................. 58 5.4 HIGHLIGHTS ................................................................................................................................................... 59 6. PATENTS ...................................................................................................................................................... 62 6.1 METHODOLOGY .............................................................................................................................................. 62 6.2 INDICATION AND TARGETS ................................................................................................................................ 64 6.3 TECHNOLOGY ................................................................................................................................................. 65 6.4 GEOGRAPHY ................................................................................................................................................... 66 6.5 TRENDS ......................................................................................................................................................... 67 6.6 HIGHLIGHTS ................................................................................................................................................... 69 7. EXPERT OPINIONS ....................................................................................................................................... 72 7.1 METHODOLOGY .............................................................................................................................................. 72 7.2 RESULTS ........................................................................................................................................................ 73 7.3 HIGHLIGHTS ................................................................................................................................................... 77 8. DISCUSSION ................................................................................................................................................. 80 8.1 WHAT IS AVAILABLE NOW AND WHAT CAN WE EXPECT? .......................................................................................... 80 8.2 CHANGES IN THE VACCINE INDUSTRY LANDSCAPE ................................................................................................... 83 8.3 PRODUCTION PLATFORMS ................................................................................................................................. 83 8.4 ENVIRONMENTAL RISKS OF GENETICALLY MODIFIED VACCINES .................................................................................. 83 8.5 SUMMARIZING STATEMENT ............................................................................................................................... 85 8.6 GENERAL RECOMMENDATIONS .......................................................................................................................... 86 ACKNOWLEDGEMENTS
Load more

Recommended publications
  • Peste Des Petits Ruminants in Africa: Meta-Analysis of the Virus Isolation in Molecular Epidemiology Studies
    Onderstepoort Journal of Veterinary Research ISSN: (Online) 2219-0635, (Print) 0030-2465 Page 1 of 15 Review Article Peste des petits ruminants in Africa: Meta-analysis of the virus isolation in molecular epidemiology studies Authors: Peste des petits ruminant (PPR) is a highly contagious, infectious viral disease of small 1,2 Samuel E. Mantip ruminant species which is caused by the peste des petits ruminants virus (PPRV), the David Shamaki2 Souabou Farougou1 prototype member of the Morbillivirus genus in the Paramyxoviridae family. Peste des petits ruminant was first described in West Africa, where it has probably been endemic in sheep and Affiliations: goats since the emergence of the rinderpest pandemic and was always misdiagnosed with 1 Department of Animal rinderpest in sheep and goats. Since its discovery PPR has had a major impact on sheep and Health and Production, University of Abomey-Calavi, goat breeders in Africa and has therefore been a key focus of research at the veterinary Abomey Calavi, Benin research institutes and university faculties of veterinary medicine in Africa. Several key discoveries were made at these institutions, including the isolation and propagation of African 2Viral Research Division, PPR virus isolates, notable amongst which was the Nigerian PPRV 75/1 that was used in the National Veterinary Research scientific study to understand the taxonomy, molecular dynamics, lineage differentiation of Institute, Vom, Nigeria PPRV and the development of vaccine seeds for immunisation against PPR. African sheep and Corresponding author: goat breeds including camels and wild ruminants are frequently infected, manifesting clinical Samuel E. Mantip, signs of the disease, whereas cattle and pigs are asymptomatic but can seroconvert for PPR.
    [Show full text]
  • Bulgaria Stops the Spread of Animal Disease with the Help of the IAEA and FAO by Laura Gil
    Infectious Diseases Bulgaria stops the spread of animal disease with the help of the IAEA and FAO By Laura Gil Bulgarian authorities at a n 2018, Bulgaria halted the spread of peste Although not transmittable to humans, local farm carrying out des petits ruminants (PPR) — a disease PPR can have a severe impact on livestock, their disease control work. Ithat can devastate livestock — thanks in part killing between 50 and 80% of infected (Photo: S. Slavchev/IAEA) to the support of the IAEA and the Food animals, mostly sheep and goats. Its high and Agriculture Organization of the United economic impact makes PPR one of the Nations (FAO). This was the first time PPR most significant livestock diseases. Also had been recorded in the European Union, known as ovine rinderpest or sheep and which made halting its spread early an goat plague, PPR originated in Africa but important goal for the region. has also been reported in Asia and the Middle East. Summer outbreak “Most European laboratories are generally In the summer of 2018, cattle breeders on neither familiar with nor prepared to deal the farms of Voden in south-eastern Bulgaria with this disease,” said Giovanni Cattoli, noticed that their animals were suffering from Head of the Animal Production and Health a disease. Soon after, authorities reported that Laboratory at the Joint FAO/IAEA Division the country was facing an outbreak of PPR. of Nuclear Techniques for Food and Within days, two Bulgarian scientists came to Agriculture. “It is exotic, off their radar. But, the IAEA to receive training and materials to luckily, Bulgaria reacted quickly, and we rapidly detect and characterize the PPR virus stepped up to support them.” using nuclear-derived techniques.
    [Show full text]
  • Assessment of Oxidative Stress in Peste Des Petits Ruminants (Ovine Rinderpest) Affected Goats
    Media Peternakan, December 2012, pp. 170-174 Online version: ISSN 0126-0472 EISSN 2087-4634 http://medpet.journal.ipb.ac.id/ Accredited by DGHE No: 66b/DIKTI/Kep/2011 DOI: 10.5398/medpet.2012.35.3.170 Assessment of Oxidative Stress in Peste des petits ruminants (Ovine rinderpest) Affected Goats A. K. Kataria* & N. Kataria Apex Centre for Animal Disease Investigation, Monitoring and Surveillance College of Veterinary and Animal Science, Rajasthan University of Veterinary and Animal Sciences, Bikaner – 334 001, Rajasthan, India (Received 28-06-2012; Reviewed 03-08-2012; Accepted 30-08-2012) ABSTRACT The aim of the present investigation was to evaluate oxidative stress in goats affected with peste des petits ruminants (PPR). The experiment was designed to collect blood samples from PPR affected as well as healthy goats during a series of PPR outbreaks which occurred during February to April 2012 in different districts of Rajasthan state (India). Out of total 202 goats of various age groups and of both the sexes, 155 goats were PPR affected and 47 were healthy. Oxidative stress was evaluated by determining various serum biomarkers viz. vitamin A, vitamin C, vitamin E, glutathione, cata- lase, superoxide dismutase, glutathione reductase and xanthine oxidase, the mean values of which were 1.71±0.09 µmol L-1, 13.02±0.14 µmol L-1, 2.22±0.09 µmol L-1, 3.03±0.07 µmol L-1, 135.12±8.10 kU L-1, 289.13±8.00 kU L-1, 6.11± 0.06 kU L-1 and 98.12±3.12 mU L-1, respectively.
    [Show full text]
  • Harnessing the Immune System to Prevent Cancer: Basic Immunologic Mechanisms & Their Application to Clinical Trials of Vaccines Part 2: the Vaccines Barbara K
    Harnessing the Immune System to Prevent Cancer: Basic Immunologic Mechanisms & Their Application to Clinical Trials of Vaccines Part 2: The Vaccines Barbara K. Dunn NCI/Division of Cancer Prevention August 3, 2020 Harnessing the Immune System to Prevent Cancer: Basic Immunologic Mechanisms and Therapeutic Approaches that are Relevant to Cancer Prevention I. Basic immunologic mechanisms II. Application to prevention & treatment of cancer 1. Antibodies: as drugs 2. Vaccines: general principles & your vaccine trials & more… I) Vaccines to prevent cancers caused by infectious agents II) Vaccines to prevent non-infection associated cancer (directed toward tumor associated antigens) Harnessing the Immune System to Prevent Cancer: Basic Immunologic Mechanisms and Therapeutic Approaches that are Relevant to Cancer Prevention I. Basic immunologic mechanisms II. Application to prevention & treatment of cancer 1. Antibodies: as drugs “passive immunity” 2. Vaccines: general principles & your vaccine trials & more… I) Vaccines to prevent cancers caused by infectious agents “active II) Vaccines to prevent immunity” non-infection associated cancer (directed toward tumor associated antigens) Harnessing the Immune System to Prevent Cancer: Basic Immunologic Mechanisms and Therapeutic Approaches that are Relevant to Cancer Prevention I. Basic immunologic mechanisms II. Application to prevention & treatment of cancer 1. Antibodies:Focus as on drugs the Antigen “passive !immunity” 2. Vaccines: general principles & your vaccine trials & more… I) Vaccines
    [Show full text]
  • The Tangible Effects of COVID-19 in Latin American Countries Boletín Del Colegio Mexicano De UROLOGIA´
    Care and management in Urology oncology: The tangible effects of COVID-19 in Latin American countries Boletín del Colegio Mexicano de UROLOGIA´ BOLETÍN DEL COLEGIO MEXICANO DE UROLOGÍA, Vol. 36, año 2021, es una revista de publicación continua editada por el Colegio Mexicano de Urología Nacional, A.C., Montecito No. 38, Piso 33, Oficina 32, Col. Nápoles, C.P. 03810 CDMX, México. Tel. directo: (01-55) 9000-8053. http://www.cmu.org.mx Director: Dr. Héctor Berea Domínguez, Editor responsable: Dr. Erick Sierra Díaz, Co-Editores: Dr. Israel Presteguín Rosas, Dr. Rafael Sandoval Gómez, Asistente editorial: Lic. Angélica M. Arévalo Zacarías. Reservas de Derechos al Uso Exclusivo del título (04-2011-12081034400-106). ISNN: (0187-4829). Licitud de Título Núm. 016. Licitud de Contenido Núm. 008, de fecha 15 de agosto de 1979, ambos otorgados por la Comisión Clasifica- dora de Publicaciones y Revistas Ilustradas de la Secretaría de Gobernación. Los conceptos vertidos en los artículos publicados en este Bletín son responsabilidad exclusiva de los autores, y no reflejan necesariamente el criterio de el Colegio Mexicano de Urología Nacional, A.C. Este número se terminó de imprimir en abril de 2021. Publicación realizada, comercializada y distribuida por Edición y Farmacia SA de CV (Nieto Editores®). Cerrada de Antonio Maceo 68, colonia Escandón, 11800 Ciudad de México. Teléfono: 5678-2811. Queda estrictamente prohibida la reproducción total o parcial de los contenidos e imágenes de la publicación sin pevia auto- rización del Colegio Mexicano de Urología Nacional, A.C. Mesa Directiva 2019-2021 Dr. Ignacio López Caballero Presidente Dr. Héctor Raúl Vargas Zamora Vicepresidente Dr.
    [Show full text]
  • Putting Into Perspective the Future of Cancer Vaccines: Targeted Immunotherapy
    Putting into Perspective the Future of Cancer Vaccines: Targeted Immunotherapy Authors: Issam Makhoul,1,2 *Thomas Kieber-Emmons2,3 1. Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA 2. Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA 3. Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA *Correspondence to [email protected] Disclosure: The authors have declared no conflicts of interest. Received: 11.11.19 Accepted: 12.02.20 Keywords: Cancer, cancer vaccine, checkpoint inhibitors. Citation: EMJ. 2020;5[3]:102-113. Abstract Pre-clinical models and human clinical trials have confirmed the ability of cancer vaccines to induce immune responses that are tumour-specific and, in some cases, associated with clinical response. However, cancer vaccines as a targeted immunotherapy strategy have not yet come of age. So, why the discordance after so much research has been invested in cancer vaccines? There are several reasons for this that include: limited tumour immunogenicity (limited targeted antigen expression, antigen tolerance); antigenic heterogeneity in tumours; heterogeneity of individual immune responses; multiple mechanisms associated with suppressed functional activity of immune effector cells, the underlying rationale for the use of immune checkpoint inhibitors; and immune system exhaustion. The success of checkpoint therapy has refocussed investigations into defining relationships between tumours and host immune systems, appreciating the mechanisms by which tumour cells escape immune surveillance and reinforcing recognition of the potential of vaccines in the treatment and prevention of cancer. Recent developments in cancer immunotherapies, together with associated technologies, for instance, the unparalleled achievements by immune checkpoint inhibitors and neo- antigen identification tools, may foster potential improvements in cancer vaccines for the treatment of malignancies.
    [Show full text]
  • ISSN: 2320-5407 Int. J. Adv. Res. 6(3), 1363-1370
    ISSN: 2320-5407 Int. J. Adv. Res. 6(3), 1363-1370 Journal Homepage: -www.journalijar.com Article DOI:10.21474/IJAR01/6806 DOI URL: http://dx.doi.org/10.21474/IJAR01/6806 RESEARCH ARTICLE A CRITIQUE ON CANCER VACCINE. Sambathkumar R1, Amala Baby2, Sudha M3 and Venkateswaramurthy N2. 1. Department of Pharmaceutics. 2. Department of Pharmacy Practice. 3. Department of Pharmacology J.K.K. Nattraja College of Pharmacy, Kumarapalayam, Tamilnadu - 638183, India. …………………………………………………………………………………………………….... Manuscript Info Abstract ……………………. ……………………………………………………………… Manuscript History The goal of a successful vaccine is to prepare the immune system for invasion of a foreign pathogen and teach them to recognize antigens as Received: 21 January 2018 well as reduce the risk of transmission. In the field of cancer, vaccines Final Accepted: 23 February 2018 are found to be the latest discovery. Provenge® (Sipuleucel-T) is the Published: March 2018 only vaccine approved by Food and Drug Administration for the Keywords:- treatment of cancer. Vaccines are an appealing therapeutic strategy Cancer vaccine, Cells, Treatment. because they are specific. In addition they stimulate the adaptive immune system, thereby producing a memory response allowing for sustained effect without repeated therapy. Revelation of a potential anticancer treatment is as yet a test to the researchers. Thus, the development of effective cancer vaccines require, thoughtful clinical trials, and scientific progress which might induce long-term specific anticancer response and could contribute to effective and lasting elimination of malignant cells. Copy Right, IJAR, 2018,. All rights reserved. …………………………………………………………………………………………………….... Introduction:- Worldwide 6.7 million deaths were reported due to cancer in 2000. But the WHO has predicted this figure to be 15 million by 2020.[1, 2] Despite great efforts to develop better therapy, in 1997 more than 6 million people worldwide died from cancer.
    [Show full text]
  • Immunological Approaches for Treatment of Advanced Stage Cancers Invariably Refractory to Drugs Talwar GP*, Jagdish C
    C al & ellu ic la n r li Im C m f u Journal of o n l o a l n o r g Talwar et al., J Clin Cell Immunol 2014, 5:4 u y o J DOI: 10.4172/2155-9899.1000247 ISSN: 2155-9899 Clinical & Cellular Immunology Review Article Open Access Immunological Approaches for Treatment of Advanced Stage Cancers Invariably Refractory to Drugs Talwar GP*, Jagdish C. Gupta, Yogesh Kumar, Kripa N. Nand, Neha Ahlawat, Himani Garg, Kannagi Rana and Hilal Bhat Talwar Research Foundation, New Delhi, India *Corresponding author: Prof. G.P. Talwar, Talwar Research Foundation, E-8, Neb Valley Neb Sarai, New Delhi 110068, India, Tel: 91-011-65022405, 65022404; E- mail: [email protected] Received date: June 18, 2014, Accepted date: August 08, 2014, Published date: August 18, 2014 Copyright: © 2014 Talwar GP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Worldwide, deaths due to cancers are taking an increasing toll. Invariably over time cancer cells become refractory to available drugs. At this stage, the tumor is largely metastasized and not amenable to radical surgery or focal radiations. This review seeks to bring out the existence of heterogeneity of cell types in each cancer, and proposes adoption of a combined approach employing more than one therapeutic agent for a more lasting treatment. Also proposed is the use of monoclonal therapeutic antibodies and vaccines against ectopically expressed key molecules for killing of cancer cells and prevention of their multiplication.
    [Show full text]
  • Ukraine of Live Animals, Their Reproductive Material, Food Products of Animal Origin and Products Not Intended for Human Consumption
    2 MINISTRY OF AGRARIAN POLICY AND FOOD OF UKRAINE EXECUTIVE ORDER ______________________ Kyiv No. ______ On approving the Requirements for importing (sending) into the customs territory of Ukraine of live animals, their reproductive material, food products of animal origin and products not intended for human consumption. In execution of Articles 3 and 30 of the Law of Ukraine "On Veterinary Medicine," Article 15 of the Law of Ukraine "On Main Principles and Requirements to Safety and Quality of Food Products," Articles 3, 4, 6 and 8 of the WTO Agreement on Sanitary and Phytosanitary Measures, Articles 59, 64 and 65 of the Association Agreement between Ukraine, on the one hand, and the European Union, the European Atomic Energy Community and their Member States, on the other hand, paragraph 34 of the Action Plan for implementation of Title IV “Trade and Trade Related Matters” of the Association Agreement between Ukraine, on the one hand, and the European Union, the European Atomic Energy Community and their Member States, on the other hand for 2016-2019 approved by Resolution of the Cabinet of Ministers of Ukraine of 18 February 2016 No. 217-r , subparagraph 2 of paragraph 4 of the Regulation on the Ministry of Agrarian Policy and Food of Ukraine approved by Resolution of the Cabinet of Ministers of Ukraine of 25 November 2015 No. 1119 I HEREBY ORDER: 1. To approve the Requirements for importing (sending) into the customs territory of Ukraine of live animals, their reproductive material, food products of animal origin and products 3 not intended for human consumption.
    [Show full text]
  • Prevelance of Peste Des Petits Ruminants Virus In
    PREVELANCE OF PESTE DES PETITS RUMINANTS VIRUS IN THE BLUE NILE STATE By Raja Eltahir Haj Omer B.V.Sc. (1996) University of Khartoum Supervisor Professor Abdel Rahim El Sayed Karrar co-Supervisor Dr. Yahia Hassan Ali A thesis submitted to the University of Khartoum in partial fulfillment of the requirements for the Degree of Master of Veterinary Medicine (M.V.M) Department of Medicine, Toxicology and Pharmacology Faculty of Veterinary Medicine University of Khartoum 2011 ﺑﺴــﻢ اﷲ اﻟﺮﺣـﻤـﻦ اﻟﺮﺣـﻴﻢ ﻗﺎل ﺗﻌﺎﻟﻰ: (ﺳـﺒﺤـﺎن اﻟﺬي ﺳـﺨﺮ ﻟﻨﺎ هﺬا وﻣﺎ آـﻨﺎ ﻟﻪ ﻣـﻘﺮﻧﲔ) ﺻﺪق اﷲ اﻟﻌﻈﻴﻢ ﺳﻮرة اﻟﺰﺧﺮف - ﺁﻳﺔ (13) LIST OF CONTENTS Page Dedication…………………………………………………………… ix Acknowledgements…………………………………………………. iix English Summary…………………………………………………….. x Arabic summary ……………………………………………………. xi List of Contents……………………………………………………… i List of Tables ……………………………………………………….. vi List of Figures………………………………………………………. vii Introduction…………………………………………………………….. 1 iii Page CHAPTER ONE: LITERATURE REVIEW 1.1. Definition………………………………………………………………. 4 1.2. Etiology………………………………………………………………… 5 1.2.1. Virus structure…………………………………………………………... 5 1.2.2. Relationship between the PPR virus and rinderpest virus………………. 6 1.3. Host Range and species variation………………………………………… 6 1.4. Historical Background……………………………………………………. 7 1.5. Epidemiology of PPR…………………………………………………… 9 1.5.1 Geographical Distribution…………………………………………….. 9 1.5.2. Transmission…………………………………………………………….. 10 1.5.3. Lineages of PPRV……………………………………………………… 11 1.5.4. Morbidity and Mortality……………………………………………… 12 1.6 Pathology………………………………………………………………… 13 1.6.1 Gross lesions…………………………………………………………… 13 1.6.2 Microscopic lesions (histopathology)………………………………… 14 1.7. Clinical Signs…………………………………………………................. 14 1.7.1. Per acute Syndrome………………………………………………… 15 page 1.7.2. Acute Syndrome…………………………………………………….. 15 1.7.3. Sub acute Syndrome………………………………………………… 17 1.8. Resistance and immunity……………………………………………… 17 1.8.1 Innate and passive immunity………………………………………… 17 1.8.2 Active immunity…………………………………………………….
    [Show full text]
  • Ppr) in in the White Nile State, Sudani
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by KhartoumSpace SURVEY AND SEROLOGICAL INVESTIGATIONS ON PESTE DES PETITS RUMINANTS (PPR) IN IN THE WHITE NILE STATE, SUDANI By Wifag Abdalla Mohamed Ali B.V.Sc. (1989) University of Khartoum Supervisor Dr. Abdelwahid Saeed Ali Babiker A thesis submitted to the University of Khartoum in partial fulfillment of the requirements for the Degree of Master of Tropical Animal Health (M.T.A.H) Department of Preventive Medicine and Veterinary Public Health Faculty of Veterinary Medicine University of Khartoum June 2009 To the soul of my father To my lovely children To my great mother Rawan To my dearest sisters, Sara Brothers and husband Ahmed With warm wide wishes with keen kind kisses i ACKNOWLEDGEMENTS First of all my thanks and praise to almighty Allah for the most beneficent, merciful for giving me health, strength and willpower to complete this study. Sincere gratitude to my supervisor Dr. Abdelwahid Saeed Ali Babiker for his guidance, advice ,attention ,kindness and unlimited help. I am grateful to Dr. Khitma Elmalik the coordinator of the master program. Department of Preventive Medicine. Faculty of Veterinary Medicine .for her encouragement and kindness during the master course. My kind regard and thanks to Dr. Yahia Hassan Ali and Dr . Intisar Kamil Saeed, Department of Virology, the Central Veterinary Research Laboratory( CVRL) Soba ,for performing ELISA. I would like to express my thanks to general directorate of Animal Resources in White Nile State, for giving me this chance and the leave of the study.
    [Show full text]
  • Molecular Evolution of Peste Des Petits Ruminants Virus1 Murali Muniraju, Muhammad Munir, Aravindhbabu R
    Molecular Evolution of Peste des Petits Ruminants Virus1 Murali Muniraju, Muhammad Munir, AravindhBabu R. Parthiban, Ashley C. Banyard, Jingyue Bao, Zhiliang Wang, Chrisostom Ayebazibwe, Gelagay Ayelet, Mehdi El Harrak, Mana Mahapatra, Geneviève Libeau, Carrie Batten, and Satya Parida Despite safe and efficacious vaccines against peste endemic to much of Africa, the Middle East, and Asia des petits ruminants virus (PPRV), this virus has emerged (1,2). The causative agent, PPRV virus (PPRV), belongs to as the cause of a highly contagious disease with serious the family Paramyxoviridae, genus Morbillivirus (3) and economic consequences for small ruminant agriculture groups with rinderpest virus (RPV), measles virus (MV), across Asia, the Middle East, and Africa. We used complete and canine distemper virus. Sheep and goats are the major and partial genome sequences of all 4 lineages of the virus hosts of PPRV, and infection has also been reported in a few to investigate evolutionary and epidemiologic dynamics of PPRV. A Bayesian phylogenetic analysis of all PPRV lin- wild small ruminant species (2). Researchers have specu- eages mapped the time to most recent common ancestor lated that RPV eradication has further enabled the spread and initial divergence of PPRV to a lineage III isolate at the of PPRV (4,5). Transmission of PPRV from infected goats beginning of 20th century. A phylogeographic approach esti- to cattle has been recently reported (6), and PPRV antigen mated the probability for root location of an ancestral PPRV has been detected in lions (7) and camels (8). These reports and individual lineages as being Nigeria for PPRV, Senegal suggest that PPRV can switch hosts and spread more read- for lineage I, Nigeria/Ghana for lineage II, Sudan for lineage ily in the absence of RPV (4,6,8).
    [Show full text]